Skip to content
Review

Newer Diabetes Medications in Older Adults with or At Risk for Cardiovascular Disease

Oct 2026 · Current Geriatrics Reports · Vol 15 · 0 citations · 125 references

TL;DR

SGLT2i and GLP-1 are safe and effective in older patients and offer cardiovascular benefits in older patients with type 2 diabetes with potential benefits of replacing other anti-diabetes agents and reducing polypharmacy.

View source

Similar papers

Open access Sep 2026

Safety of Sodium/Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes and CKD.

In two large real-world cohorts of patients with T2D and CKD, the tree-based scan statistic identified previously known adverse events, but no new safety signals associated with SGLT2 inhibitor use compared with GLP-1RA use.

J. Ortega-Montiel, Wajd Alkabbani, Georg Hahn et al. · 0 citations
Review Nov 2026

Association of GLP-1 receptor agonist and SGLT2 inhibitor use with outcomes in patients with type 2 diabetes undergoing pacemaker implantation.

AIMS Heart failure (HF) remains prevalent following pacemaker implantation, with patients with type 2 diabetes mellitus (T2DM) representing a particularly vulnerable population. Whether use of contemporary glucose-lowering therapies is associated with subsequent clinical outcomes has not been well characterized. We inv...

Yuval Avidan, Matan Jonas, Dana Hadar et al. · 0 citations
Sep 2026

Modern glucose-lowering drugs SGLT2 inhibitors and GLP-1 agonists in the prevention of cardiovascular disease and dementia in patients with diabetes and metabolic disorders

A clinical pharmacological analysis of current data is presented, discussing the mechanisms of action, clinical efficacy, safety, and strategies for personalized use of SGLT2 inhibitors and GLP-1 RAs in preventing cardiovascular and neurodegenerative complications in patients with type 2 diabetes and metabolic disorder...

E. N. Saykina, A. O. Kenkishvili, M. Maksimov et al. · 0 citations
Review Oct 2026

The use of glucagon-like peptide-1 agonists as a treatment for obesity in older people: risks and benefits.

PURPOSE OF REVIEW Obesity is an increasingly important health problem in older adults (≥65 years) and is associated with osteoarthritis, impaired mobility, reduced quality of life, cardiovascular disease, and other age-related comorbidities. This narrative review summarizes the current evidence regarding the benefits a...

M. Kaşkal, U. Alam, Gregory Y. H. Lip · 0 citations
Oct 2026

Safety of Sodium-Glucose Cotransporter 2 Inhibitors in Older Adults With Type 2 Diabetes: A Cohort Study.

OBJECTIVE Sodium-glucose cotransporter 2 inhibitors (SGLT2is) have demonstrated cardiorenal benefits in individuals with type 2 diabetes, but safety data in older adults remain limited. We evaluated the real-world safety of SGLT2is compared with dipeptidyl peptidase 4 inhibitors (DPP-4is) among individuals aged ≥75 yea...

Hanin Harbi, Michael Nesrallah, G. Carney et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.